GLP-1 & Metabolic Health — Latest Articles

Bone Health and GLP-1s: New Data Clears Up 2026 Confusion

Early 2026 warnings about GLP-1 induced osteoporosis clash with new August 2026 research showing a 21% drop in fracture risk for Type 2 diabetics.

BMJ Study Links GLP-1 Drugs to Higher Hair Loss Risk

Major new study links popular weight loss drugs to increased alopecia risk. Analysis of 550,000 patients shows higher rates of hair loss compared to other diabetes meds.

Shifting GLP-1 Delivery: Oral Approvals and Monthly Dosing in 2026

Explore how 2026 marks a pivotal shift in GLP-1 administration, featuring the first FDA-approved oral non-peptide option, monthly injectable pipelines, and new clinical perspectives on metabolic health.

Lilly's Retatrutide Hits 30% Weight Loss Threshold in Phase 3

Eli Lilly Reports Breakthrough Data from TRIUMPH-1 Obesity Trial Eli Lilly has released top-line results from the pivotal Phase 3 TRIUMPH-1 trial for retatrutid...

Kidney Benefits of Semaglutide Solidify With 2026 Data

A Paradigm Shift in Renal Care While the metabolic advantages of glucagon-like peptide-1 (GLP-1) receptor agonists initially dominated clinical discourse, devel...

Medicare GLP-1 Bridge Launches July 2026: Coverage and Eligibility

On Monday, July 1, 2026, the path to metabolic health care for older Americans shifted dramatically. After years of legislative debate and funding uncertainties...

Untitled

Untitled

GLP-1s Shift Focus: Heart Benefits Emerge for Type 1 Diabetes

A Paradigm Shift in Type 1 Diabetes Care In a development that could redefine therapeutic standards for millions, recent evidence indicates that glucagon-like p...

Untitled

Untitled

Beyond Efficacy: The Real-World Challenges of GLP-1 Adherence

In the rapidly evolving landscape of metabolic health, the arrival of dual GIP/GLP-1 receptor agonists and potent GLP-1 analogues has marked a therapeutic water...